Communicating with women about menstrual cycle symptoms

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 53, Issue 11, 2008, Pages 837-846

  Ballagh, Susan A ^a,b   Heyl, Adair ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Counseling; Dysmenorrhea; Efficiency (productivity); Premenstrual syndrome

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; ANXIOLYTIC AGENT; CITALOPRAM; CLOMIPRAMINE; DANAZOL; DEPOT MEDROXYPROGESTERONE ACETATE; DESOGESTREL; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESCITALOPRAM; ETHINYLESTRADIOL; FISH OIL; FLUOXETINE; GESTAGEN; GLYCERYL TRINITRATE; GONADORELIN AGONIST; IBUPROFEN; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ABSENTEEISM; ACUPRESSURE; ACUPUNCTURE; CLINICAL TRIAL; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DYSMENORRHEA; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; HYSTERECTOMY; LOW DRUG DOSE; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; OVARIECTOMY; PATIENT INFORMATION; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRANSCUTANEOUS NERVE STIMULATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; DYSMENORRHEA; FEMALE; HUMANS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PREMENSTRUAL SYNDROME; YOUNG ADULT;

EID: 57849124123     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Centers for Disease Control and Prevention: Family planning methods and practice: Africa. Second edition. Atlanta, GA, CDC, 2000
2. Steiner M, Born L: Psychiatric aspects of the menstrual cycle. In Women's Mental Health. Edited by SG Kornstein, AH Clayton. New York, NY, Guilford Press, 2002, pp 48-69
3. Williams CL, Stancel GM: Estrogens and progestins. In Goodman and Gilman's The Pharmacological Basis of Therapeutics. Edited by J Hardman, L Limbird. New York, NY, McGraw-Hill, 1996, pp 1411-1415
4. Couchman GM, Hammond CB: Physiology of reproduction. In Danforth's Obstetrics and Gynecology. Edited by JR Scott, et al. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 47-63
5. Magos AL: Effects and analysis of the menstrual cycle. J Biomed Eng 1988;10:105-109
6. Magos AL, Studd JW: Assessment of menstrual cycle symptoms by trend analysis. Am J Obstet Gynecol 1986;155:271-277
7. Harlow SD, Park M: A longitudinal study of risk factors for the occurrence, duration, and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996;103:1134-1142
8. Dawood MY: Dysmenorrhea. Clin Obstet Gynecol 1990;33:168-178
9. Kaunitz AM: Menstruation: Choosing whether...and when. Contraception 2000;62:277-284
10. Davis AR, Westhoff CL: Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 2001;14:3-8
11. French L: Dysmenorrhea. Am Fam Physician 2005;71:285-291
12. Chen C, Cho SI, Damokosh AI, et al: Prospective study of exposure to environmental tobacco smoke and dysmenorrhea. Environ Health Perspect 2000;108:1019-1022
13. Teperi J, Rimpela M: Menstrual pain, health and behaviour in girls. Soc Sci Med 1989;29:163-169
14. Stromberg P, Akerlund M, Forsling ML, et al: Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. Acta Obstet Gynecol Scand 1984;63:533-538
15. Nigam S, Benedetto C, Zonca M, et al: Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 1991;4:137-141
16. Liedman R, Skillern L, James I, et al: Validation of a test model of induced dysmenorrhea. Acta Obstet Gynecol Scand 2006;85:451-457
17. Koike H, Ikenoue T, Mori N: Studies on prostaglandin production relating to the mechanism of dysmenorrhea in endometriosis. Nippon Naibunpi Gakkai Zasshi 1994;70:43-56
18. Sundell G, Milsom I, Andersch B: Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990;97:588-594
19. Anderson B, Milsom I: An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982;144:655-660
20. Thomas SL, Ellertson C: Nuisance or natural and healthy: Should monthly menstruation be optional for women? Lancet 2000;355:922-924
21. Campbell MA, McGrath PJ: Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. Clin J Pain 1999;15:313-320
22. Akin MD, Weingand KW, Hengehold DA, et al: Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001;97:343-349
23. Akin M, Price W, Rodriguez G Jr, et al: Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004;49:739-745
24. Harel Z, Biro FM, Kottenhahn RK, et al: Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-1338
25. Fujiwara T: Skipping breakfast is associated with dysmenorrhea in young women in Japan. Int J Food Sci Nutr 2003;54:505-509
26. Kotani N, Oyama T, Sakai I, et al: Analgesic effect of a herbal medicine for treatment of primary dysmenorrheal - A double-blind study. Am J Chin Med 1997;25:205-212
27. Wilson ML, Murphy PA: Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001;(3):CD002124
28. Marjoribanks J, Proctor ML, Farquhar C: Nonsteroidal antiinflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev 2003;(4):CD001751
29. Benassi L, Bertani D, Avanzini A: An attempt at real prophylaxis of primary dysmenorrhea: Comparison between meclofenamate sodium and naproxen sodium. Clin Exp Obstet Gynecol 1993;20:102-107
30. Hendrix SL, Alexander NJ: Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002;66:393-399
31. Ekstrom P, Juchnicka E, Laudanski T, et al: Effect of an oral contraceptive in primary dysmenorrheal - Changes in uterine activity and reactivity to agonists. Contraception 1989;40:39-47
32. Hauksson A, Ekstrom P, Juchnicka E, et al: The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1089;68:31-34
33. Proctor ML, Roberts H, Farquhar CM: Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001;(4):CD002120
34. Sulak PJ, Cressman BE, Waldrop E, et al: Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-183
35. Morgan PJ, Kung R, Tarshis J: Nitroglycerin as a uterine relaxant: A systematic review. J Obstet Gynaecol Can 2002;24:403-409
36. Kaplan B, Rabinerson D, Lurie S, et al: Clinical evaluation of a new model of a transcutaneous electrical nerve stimulation device for the management of primary dysmenorrhea. Gynecol Obstet Invest 1997;44:255-259
37. Proctor ML, Hing W, Johnson TC, et al: Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2004;(3):CD002119
38. Wilson ML, Farquhar CM, Sinclair OJ, et al: Surgical Interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2000;(2):CD001896
39. Dopkins JE, Hillard PJA: Menstruation in teenagers: How to recognize and treat abnormalities. Women's Health in Primary Care 2003;6:295-304
40. Kissling EA: "That's just a basic teen-age rule": Girls' linguistic strategies for managing the menstrual communication taboo. J Appl Comm Res 1996;24:292-309
41. Mutha S, Allen C, Welch M: Toward Culturally Competent Care: A Toolbox for Teaching Communication Strategies. San Francisco, CA, Center for Health Professions, University of California, 2002
42. Buckley T, Gottlieb A (editors): A critical appraisal of theories of menstrual symbolism. In Blood Magic: The Anthropology of Menstruation. Los Angeles, University of California Press, pp 1-50
43. Lu ZJ: The relationship between menstrual attitudes and menstrual symptoms among Taiwanese women. J Adv Nurs 2001;33:621-628
44. Roberts TA: Female trouble: The menstrual self-evaluation scale and women's self-objectification. Psychol Women Q 2004;28:22-26
45. Lafta RK: Practitioner gender preference among gynecologic patients in Iraq. Health Care Women Int 2006;27:125-130
46. Purnell LD, Paulanka BJ: The Purnell model for cultural competence. In Guide to Culturally Competent Health Care. Edited by R Martone, D Caroll. Philadelphia, FA Davis, 2005
47. Beckman HB, Frankel RM: The effect of physician behavior on the collection of data. Ann Intern Med 1984;101:692-696
48. Svab I, Katic M, Cuk V: The time used by the patient when he/she talks without interruptions. Aten Primaria 1993;11:175-177
49. Tallman K, Janisse T, Frankel RM, et al: Communication practices of physicians with high patient-satisfaction ratings. The Permanente Journal 2007;11:1-16
50. Ogden J, Bavalia K, Bull M, et al: "I want more time with my doctor": A quantitative study of time and the consultation. Fam Pract 2004;21:479-483
51. Endicott J, Halbreich U, Schacht S, et al: Premenstrual changes and affective disorders. Psychosom Med 1981;43:519-529
52. Deuster PA, Adera T, South-Paul J: Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999;8:122-128
53. Freeman EW: Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology (suppl 3) 2003;28:25-37
54. Dean BB, Borenstein JE: A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. J Occup Environ Med 2004;46:649-656
55. Borenstein J, Chiou CF, Dean B, et al: Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005;47:26-33
56. American College of Obstetricians and Gynecologists: ACOG Committee on Practice Bulletins-Gynecology: Premenstrual syndrome: Clinical management guidelines for obstetrician-gynecologists. ACOG Pract Bull 2000;15:448-455
57. American Psychiatric Association: Premenstrual Dysphoric Disorder. Appendix B: Criteria Sets and Axes Provided for Further Study. In Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000. DOI: 10.1176/appi.books.9780890423349.5088. Available at http://www.psychiatryonline. com/content.aspx?aID=5272. Accessed Feb 28, 2008
58. Halbreich U: The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology (suppl) 2003;28:55-99
59. Rubinow DR, Roy-Byrne P: Premenstrual syndromes: Overview from a methodologic perspective. Am J Psychiatry 1984;141:163-172
60. Vujovic S, Zidverc J, Stojanovic M, et al: Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures. Gynecol Endocrinol 2005;21:243-247
61. Matsumoto T, Ushiroyama T, Morimura M, et al: Autonomic nervous system activity in the late luteal phase of eumenorrheic women with premenstrual symptomatology. J Psychosom Obstet Gynaecol 2006;27:131-139
62. Haywood A, Slade P, King H: Psychosocial associates of premenstrual symptoms and the moderating role of social support in a community sample. J Psychosom Res 2007;62:9-13
63. Connolly M: Premenstrual syndrome: An update on definitions, diagnosis and management. Adv Psychiatr Treat 2001;7:469-477
64. Gallant SJ, Popiel DA, Hoffman DM, et al: Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder: Part H. What makes a "real" difference? Psychosom Med 1992;54:167-181
65. Halbreich U, Borenstein J, Pearlstein T, et al: The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Pyschoneuroendocrinology (suppl 3) 2003;28:1-23
66. Pearlstein TB, Halbreich U, Batzar ED, et al: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-109
67. Perry BL, Miles D, Burruss K, et al: Premenstrual symptomatology and alcohol consumption in college women. J Stud Alcohol 2004;65:464-408
68. Saunders KE, Hawton K: Suicidal behaviour and the menstrual cycle. Psychol Med 2006;36:901-912
69. Targum SD, Caputo KP, Ball SK: Menstrual cycle phase and psychiatric admissions. J Affect Disord 1991;22:49-53
70. Kraemer GR, Kraemer RR: Premenstrual syndrome: Diagnosis and treatment experiences. J Womens Health 1998;7:893-907
71. Freeman EW, Rickeis K: Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999;156:1403-1408
72. Steiner M, Steinberg S, Stewart D, et al: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-1534
73. Cohen LS, Soares CN, Lyster A, et al: Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004;24:540-543
74. Diegoli MS, da Fonseca AM, Diegoli CA, et al: A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998;62:63-67
75. Freeman EW, Rickels K, Sondheimer SJ, et al: A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-57
76. Mezrow G, Shoupe D, Spicer D, et al: Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994;62:932-937
77. Casper RF, Hearn MT: The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990;162:105-109
78. Casson P, Hahn PM, Van Vugt DA, et al: Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990;162:99-105 79. Zoloft product label. Available at: http://www.pfizer.com/files/products/ uspi_zoloft.pdf#page=43. Accessed July 19, 2007
79. PAXIL (paroxetine hydrochloride) tablets and oral suspension package insert, GlaxoSmithKline, Research Triangle Park, NC, 2005
80. Sulak PJ, Kuehl TJ, Ortiz M, et al: Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002;186:1142-1149
81. Freeman EW, Kroll R, Rapkin A, et al: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-569
82. Pearlstein TB, Bachmann GA, Zacur HA, et al: Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421
83. Rapkin A: A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology (suppl 3) 2003;28:39-53
84. Yonkers KA, Brown C, Pearlstein TB, et al: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501
85. Sulak PJ: Ovulation suppression of premenstrual symptoms using oral contraceptives. Am J Manag Care 2005;11:S492-S497
86. Freeman EW, Borisute H, Deal L, et al: A continuous-use regimen of levonorgestrel/ethinyl estradiol significantly alleviates cycle-related symptoms: Results of a phase 3 study (abstr 0-59). Fertil Steril (suppl 1) 2005;84:S25
87. Levinson W, Roter D: Physicians' psychosocial beliefs correlate with their patient communication skills. J Gen Intern Med 1995;10:375-379
88. Dienes CL, Morrissey SL, Wilson, AV: Health care experience of African American teen women in eastern North Carolina. Family Med 2004;36:346-351
89. Boehm FH: Keeping the human touch. Fam Prac Manag 2003;10:66
90. Kirchner JT: Patient compliance in filling new prescriptions. Am Fam Phys 2000;62:201
91. Case AM, Reid RL: Effects of the menstrual cycle on medical disorders. Arch Intern Med 1998;158:1405-1412
92. MacGregor EA, Chia H, Vohrah RC, et al: Migraine and menstruation: A pilot study. Cephalalgia 1990;10:305-310
93. Mannix LK, Calhoun AH, Calhoun AH: Menstrual migraine. Curr Treat Options Neurol 2004;6:489-498
94. Oguzulgen IK, Turktas H, Erbas D: Airway inflammation in premenstrual asthma. J Asthma 2002;39:517-522
95. Sulak PJ, Scow RD, Preece C, et al: Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266
96. Rosenberg MJ, Waugh MS: Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-582
97. Barrier PA, Li JT, Jensen NM: Two words to improve physician-patient communication: What else? Mayo Clin Proc 2003;78:211-214
98. Margalit RS, Roter D, Dunevant MA, et al: Electronic medical record use and physician-patient communication: An observational study of Israeli primary care encounters. Patient Educ Couns 2006;61:134-141
99. Stewart M, Brown JB, Boon H, et al: Evidence on patient-doctor communication. Cancer Prev Control 1999;3:25-30
100. Bikker AP, Mercer SW, Reilly D: A pilot prospective study on the consultation and relational empathy, patient enablement, and health changes over 12 months in patients going to the Glasgow Homoeopathic Hospital. J Altern Complement Med 2005;11:591-600
101. Moore EE, Harger JM, Rock JA, et al: Management of pelvic endometriosis with low-dose danazol. Fertil Steril 1981;36:15-19
102. Schlaff WD, Carson SA, Luciano A, et al: Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006;85:314-325
103. Lethaby AE, Cooke I, Rees M: Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;(4):CD002126
104. American College of Obstetricians and Gynecologists: Guidelines for Women's Health Care. Second edition. Washington, DC, ACOG, 2002